An upper and lower bound of the Medication Possession Ratio

Patient Preference and Adherence

Volumn 11, Issue , 2017, Pages 1469-1478

  Sperber, Christian M ^a   Samarasinghe, Suren R ^a   Lomax, Grace P ^a  

^a Patient Connect Limited   (United Kingdom)

Author keywords

Adherence; Administrative claims data; Compliance; MPR; Pharmacy claims; Quantitative calculation

Indexed keywords

ADULT; CALCULATION; COHORT ANALYSIS; HUMAN; LOW DRUG DOSE; PHARMACY;

EID: 85029217142     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S136890     Document Type: Article

References (27)

1. Clark MA, ed. Lippincott’s Illustrated Reviews. Pharmacology. 5th ed. Baltimore, MD: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2012.
2. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11(7):449–457.
3. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review: Compliance in cardiovascular disease. Int J Clin Pract. 2007;62(1):76–87.
4. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177–186.
5. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886–891.
6. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001;52(6):805–811.
7. Muszbek N, Brixner D, Benedict A, Keskinaslan A, Khan ZM. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review: Economics of noncompliance in CVD. Int J Clin Pract. 2008;62(2):338–351.
8. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521–530.
9. Lee TH. Eulogy for a Quality Measure. N Engl J Med. 2007;357(12):1175–1177.
10. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105–116.
11. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565–574.
12. Benner JS. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455.
13. Hamilton RA, Briceland LL. Use of prescription-refill records to assess patient compliance. Am J Hosp Pharm. 1992;49(7):1691–1696.
14. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health. 2009;12(6):989–995.
15. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7–8):1280–1288.
16. Lam WY, Fresco P. Medication adherence measures: an overview. Bio Med Res Int. 2015;2015:1–12.
17. Halpern MT, Khan ZM, Schmier JK, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension. 2006;47(6):1039–1048.
18. Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15(7):457–464.
19. Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009;43(1):36–44.
20. Franklin JM, Shrank WH, Pakes J, et al. Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. Med Care. 2013;51(9):789–796.
21. Kozma C, Dickson M, Phillips AL, Meletiche DM. Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adherence. 2013;7:509–516.
22. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients: Med Care. 2008;46(11):1125–1133.
23. Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med. 2007;20(1):72–80.
24. Silva NL, Ribeiro E, Navarro JL, Zanini AC. Compliance with treatment: related-issues and insights for pharmacist intervention. Braz J Pharm Sci. 2011;47(1):1–12.
25. Fairman KA. Evaluating medication adherence: which measure is right for your program? J Manag Care Pharm. 2000;6(6):499–506.
26. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279(18):1458–1462.
27. Blandford L. Analyzing variations in medication compliance related to individual drug, drug class, and prescribing physician. J Manag Care Pharm. 1999;5(1):47–51.